FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385514367> ?p ?o ?g. }

• W4385514367 abstract "Importance Only 1 randomized clinical trial has shown the superiority of immune checkpoint inhibitors in patients with deficient mismatch repair and/or microsatellite instability (dMMR/MSI) metastatic colorectal cancer (mCRC) in the first-line setting. Objectives To determine whether avelumab (an anti–programmed cell death ligand 1 antibody) improves progression-free survival (PFS) compared with standard second-line chemotherapy in patients with dMMR/MSI mCRC. Design, Setting, and Participants The SAMCO-PRODIGE 54 trial is a national open-label phase 2 randomized clinical trial that was conducted from April 24, 2018, to April 29, 2021, at 49 French sites. Patients with dMMR/MSI mCRC who experienced progression while receiving standard first-line therapy were included in the analysis. Interventions Patients were randomized to receive standard second-line therapy or avelumab every 2 weeks until progression, unacceptable toxic effects, or patient refusal. Main Outcome and Measures The primary end point was PFS according to RECIST (Response Evaluation Criteria in Solid Tumours), version 1.1, evaluated by investigators in patients with mCRC and confirmed dMMR and MSI status who received at least 1 dose of treatment (modified intention-to-treat [mITT] population). Results A total of 122 patients were enrolled in the mITT population. Median age was 66 (IQR, 56-76) years, 65 patients (53.3%) were women, 100 (82.0%) had a right-sided tumor, and 52 (42.6%) had BRAF V600E –mutated tumors. There was no difference in patients and tumor characteristics between treatment groups. No new safety concerns in either group were detected, with fewer treatment-related adverse events of at least grade 3 in the avelumab group than in the chemotherapy group (20 [31.7%] vs 34 [53.1%]; P = .02). After a median follow-up of 33.3 (95% CI, 28.3-34.8) months, avelumab was superior to chemotherapy with or without targeted agents with respect to PFS (15 [24.6%] vs 5 [8.2%] among patients without progression; P = .03). Rates of PFS rates at 12 months were 31.2% (95% CI, 20.1%-42.9%) and 19.4% (95% CI, 10.6%-30.2%) in the avelumab and control groups, respectively, and 27.4% (95% CI, 16.8%-39.0%) and 9.1% (95% CI, 3.2%-18.8%) at 18 months. Objective response rates were similar in both groups (18 [29.5%] vs 16 [26.2%]; P = .45). Among patients with disease control, 18 (75.7%) in the avelumab group compared with 9 (19.1%) in the control group had ongoing disease control at 18 months. Conclusions The SAMCO-PRODIGE 54 phase 2 randomized clinical trial showed, in patients with dMMR/MSI mCRC, better PFS and disease control duration with avelumab over standard second-line treatment, with a favorable safety profile. Trial Registration ClinicalTrials.gov Identifier: NCT03186326" @default.
• W4385514367 created "2023-08-04" @default.
• W4385514367 creator A5001170954 @default.
• W4385514367 creator A5001847828 @default.
• W4385514367 creator A5005765894 @default.
• W4385514367 creator A5007381211 @default.
• W4385514367 creator A5007579310 @default.
• W4385514367 creator A5012517099 @default.
• W4385514367 creator A5013388524 @default.
• W4385514367 creator A5013525685 @default.
• W4385514367 creator A5015826379 @default.
• W4385514367 creator A5015951291 @default.
• W4385514367 creator A5016604958 @default.
• W4385514367 creator A5017079089 @default.
• W4385514367 creator A5020520466 @default.
• W4385514367 creator A5021530108 @default.
• W4385514367 creator A5022092205 @default.
• W4385514367 creator A5022288769 @default.
• W4385514367 creator A5022898517 @default.
• W4385514367 creator A5023466579 @default.
• W4385514367 creator A5024180743 @default.
• W4385514367 creator A5025066980 @default.
• W4385514367 creator A5026067442 @default.
• W4385514367 creator A5026722062 @default.
• W4385514367 creator A5028160510 @default.
• W4385514367 creator A5030243619 @default.
• W4385514367 creator A5032193447 @default.
• W4385514367 creator A5035093719 @default.
• W4385514367 creator A5036106894 @default.
• W4385514367 creator A5037282242 @default.
• W4385514367 creator A5039161609 @default.
• W4385514367 creator A5040688022 @default.
• W4385514367 creator A5040985815 @default.
• W4385514367 creator A5042306519 @default.
• W4385514367 creator A5043463827 @default.
• W4385514367 creator A5043601545 @default.
• W4385514367 creator A5043962640 @default.
• W4385514367 creator A5045047864 @default.
• W4385514367 creator A5045861697 @default.
• W4385514367 creator A5045889385 @default.
• W4385514367 creator A5046140326 @default.
• W4385514367 creator A5047740666 @default.
• W4385514367 creator A5048259305 @default.
• W4385514367 creator A5049661683 @default.
• W4385514367 creator A5053060122 @default.
• W4385514367 creator A5054195758 @default.
• W4385514367 creator A5057598744 @default.
• W4385514367 creator A5057720244 @default.
• W4385514367 creator A5058126689 @default.
• W4385514367 creator A5059868956 @default.
• W4385514367 creator A5060536774 @default.
• W4385514367 creator A5060657856 @default.
• W4385514367 creator A5063300327 @default.
• W4385514367 creator A5064043208 @default.
• W4385514367 creator A5066162032 @default.
• W4385514367 creator A5066354699 @default.
• W4385514367 creator A5067244473 @default.
• W4385514367 creator A5067565814 @default.
• W4385514367 creator A5069539916 @default.
• W4385514367 creator A5070426915 @default.
• W4385514367 creator A5070674412 @default.
• W4385514367 creator A5072479267 @default.
• W4385514367 creator A5073459177 @default.
• W4385514367 creator A5073655770 @default.
• W4385514367 creator A5074133896 @default.
• W4385514367 creator A5074346281 @default.
• W4385514367 creator A5076878654 @default.
• W4385514367 creator A5077000250 @default.
• W4385514367 creator A5077773931 @default.
• W4385514367 creator A5077844357 @default.
• W4385514367 creator A5078571719 @default.
• W4385514367 creator A5078680535 @default.
• W4385514367 creator A5079480540 @default.
• W4385514367 creator A5080821730 @default.
• W4385514367 creator A5083252572 @default.
• W4385514367 creator A5087797120 @default.
• W4385514367 creator A5088235227 @default.
• W4385514367 creator A5089392584 @default.
• W4385514367 creator A5089818289 @default.
• W4385514367 creator A5090375155 @default.
• W4385514367 creator A5092587866 @default.
• W4385514367 date "2023-08-03" @default.
• W4385514367 modified "2023-10-18" @default.
• W4385514367 title "Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability" @default.
• W4385514367 cites W1504535992 @default.
• W4385514367 cites W1926715094 @default.
• W4385514367 cites W1940241680 @default.
• W4385514367 cites W1979425223 @default.
• W4385514367 cites W2004816062 @default.
• W4385514367 cites W2021382013 @default.
• W4385514367 cites W2033577259 @default.
• W4385514367 cites W2052228812 @default.
• W4385514367 cites W2099751212 @default.
• W4385514367 cites W2115735904 @default.
• W4385514367 cites W2121847974 @default.
• W4385514367 cites W2128793721 @default.
• W4385514367 cites W2132105937 @default.
• W4385514367 cites W2142300779 @default.
• W4385514367 cites W2159064822 @default.
• W4385514367 cites W2160373161 @default.

• next